AI-Driven Drug Discovery
AI-Driven Drug Discovery
The collaboration leverages Insilico's end-to-end AI-driven Pharma.AI platform to discover new small-molecule drug candidates for multiple targets, as well as EQRx's innovative business model to accelerate drug development and speed access to new medicines at affordable prices.
Insilico Medicine, a clinical-stage, end-to-end artificial intelligence (AI)-focused drug discovery company, announced today a strategic collaboration with EQRx, a company committed to developing and delivering innovative medicines to patients at radically lower prices.
The collaboration will combine Insilico's Pharma.AI platform, de novo small-molecule design and synthesis with EQRx's clinical development and commercialization expertise. EQRx and Insilico will enter into a joint development partnership in which each party will be entitled to profit share proportional to its respective level of investment.
Under the collaboration agreement, the parties will identify and select up to three therapeutic targets leveraging Insilico's AI-driven platform Pharma.AI. Insilico will lead drug discovery from small-molecule hit identification through lead optimization and preclinical candidate nomination to investigational new drug (IND) application. EQRx will assume responsibility for directing clinical development, regulatory affairs and commercialization. Insilico has the option to invest in product candidates at various clinical development stages in exchange for increasing commercialization profits.
Dr. Alex Zhavoronkov, founder and CEO of Insilico Medicine, said, "Both EQRx and Insilico Medicine are committed to accelerating the discovery and development of new medicines and making effective therapeutics more accessible and affordable. This partnership will combine our end-to-end AI-enabled drug discovery capabilities with EQRx's innovative partnership model and clinical development and patient access expertise to accelerate the discovery and development of innovative treatments."
Carlos Garcia-Echeverria, head of Rx Creation at EQRx, said, "We are pleased to partner with Insilico Medicine, a leading company in AI-based drug discovery. This collaboration will further expand our early-stage R&D efforts to accelerate potential growth while continuing to apply today's best innovations in biomedical sciences and digital solutions to discover high-quality, innovative and more affordable medicines."
